Financial Performance - Revenue for the year ended December 31, 2022, was RMB 83.6 million, representing a 3.0% increase from RMB 81.2 million in 2021[11] - Gross profit for 2022 was RMB 69.8 million, with a gross margin of 83.5%, down from 85.0% in 2021[11] - The company reported a loss attributable to shareholders of RMB 1,346.0 million, a 112.4% increase compared to a loss of RMB 633.6 million in 2021[11] - The adjusted loss per share for 2022 was RMB 0.11, an increase of 37.5% from RMB 0.08 in 2021[11] - Total revenue for the year ended December 31, 2022, was RMB 83.6 million, a slight increase from RMB 81.2 million in 2021, driven primarily by sales of the FlashPressure caFFR pressure sensor[46] - Gross profit increased from RMB 69.0 million in 2021 to RMB 69.8 million in 2022, with a gross margin of 83.5% in 2022 compared to 85.0% in 2021[47] - Research and development expenses surged by approximately 63.8% from RMB 27.0 million in 2021 to RMB 44.2 million in 2022, mainly due to increased employee benefits and professional service costs[49] - Sales expenses decreased by about 4.8% from RMB 70.1 million in 2021 to RMB 66.8 million in 2022, primarily due to a reduction in one-time share-based payment expenses[52] - General and administrative expenses decreased from RMB 115.2 million in 2021 to RMB 109.3 million in 2022, a year-on-year decline of approximately 5.1%[55] - Other income rose from RMB 0.4 million in 2021 to RMB 5.3 million in 2022, primarily due to an increase in government subsidies[56] - The net cash used in operating activities was RMB 111.2 million, mainly due to significant R&D, administrative, and sales expenses[60] - Cash and cash equivalents decreased from RMB 559.1 million in 2021 to RMB 91.1 million in 2022, a reduction of RMB 468.0 million[61] - The company recorded a loss of RMB 1,346.0 million for the year ended December 31, 2022, compared to a loss of RMB 633.6 million for the year ended December 31, 2021[59] - The fair value loss of financial liabilities increased significantly from RMB 493.9 million in 2021 to RMB 1,210.9 million in 2022 due to the rise in the company's valuation[58] Assets and Liabilities - Non-current assets increased by 34.6% to RMB 86,897,000 in 2022 from RMB 64,547,000 in 2021[13] - Total assets rose by 7.8% to RMB 690,330,000 in 2022 compared to RMB 640,192,000 in 2021[13] - Total liabilities decreased by 94.9% to RMB 71,694,000 in 2022 from RMB 1,414,676,000 in 2021[13] - Total equity improved significantly to RMB 618,636,000 in 2022 from a loss of RMB 774,484,000 in 2021, marking a change of 179.9%[13] Product Development and Market Position - The caFFR system achieved over 95% accuracy and a convenient operation time of less than five minutes, establishing a leading position in the domestic FFR measurement market[5] - The company plans to expand the indications for the caFFR system to include acute STEMI, acute NSTEMI, and HFpEF patients[5] - The caIMR system is expected to become the world's first commercially approved minimally invasive IMR measurement system in 2023[5] - The company aims to launch its vascular interventional surgical robot by 2024, integrating all clinical applications for automated PCI processes[5] - The caFFR system achieved a clinical accuracy rate of 93.81% in 2022, with over 1,000 hospitals using the system by year-end[17][19] - The caIMR system entered the special approval pathway of the National Medical Products Administration in April 2022, with commercialization expected in Q2 2023[17] - By the end of 2022, the caFFR system was commercialized in 30 provinces and regions in China, with 21 provinces covered by medical insurance[19] - The company is actively seeking investment and acquisition targets to enhance its product lineup and expand its precision diagnosis and treatment product lines[22] - The global FFR measurement market is projected to grow from approximately USD 504.1 million in 2020 to about USD 1,200.0 million by 2025, with a compound annual growth rate (CAGR) of 18.9%[26] - The Chinese FFR measurement market is expected to rise from RMB 78.6 million in 2020 to approximately RMB 2,385.7 million by 2025, reflecting a CAGR of 97.9%[26] Research and Development - The R&D team consists of over 100 members, accounting for approximately one-third of the total workforce, focusing on innovative products in the field of interventional precision therapy[34] - As of December 31, 2022, the company holds 102 approved patents and has 178 patents pending, including 129 in China and 49 overseas[34] - The company is considering investments and acquisitions within the industry to expand its product pipeline and introduce innovative products[23] - The IMR measurement market is still in its early stages, and the company plans to focus on training for doctors, patients, and hospital managers regarding the caIMR system[27] Corporate Governance and Management - The company has a management team with over 16 years of experience in compliance, investment, and financing, enhancing its strategic capabilities[83] - The company’s Vice President, Ms. Gu Yang, has been with the group since March 2021, focusing on human resources management[87] - The company’s independent non-executive director, Mr. Liao Chuanjiang, has over 20 years of experience in accounting, auditing, and management, providing independent oversight[94] - The company has a strong governance structure with a diverse board, including members with extensive backgrounds in finance and investment management[89][92] - The company is focused on compliance and regulatory communication, ensuring adherence to market standards[84] - The company’s strategic direction is supported by a board that provides investment strategies and governance guidance[89][92] Shareholder Information - As of December 31, 2022, Mr. Huo Yunfei holds 214,749,000 shares, representing 18.39% of the company[155] - Mr. Lü Yonghui holds 30,937,000 shares, accounting for 2.65% of the company[155] - The company has a total of 1,167,799,000 shares issued as of December 31, 2022[174] - The company has significant ownership concentration, with several shareholders holding around 5.05% each[171] - The ownership structure includes various partnerships and trusts, indicating a complex ownership arrangement[172] - The company is indirectly controlled by Ping An Group, which holds significant stakes in related investment entities[176] Future Outlook and Challenges - The company remains optimistic about the market outlook in mainland China and Hong Kong for 2023 despite recent challenges[45] - The group has faced significant operational losses since its inception, which may continue in the foreseeable future as it expands product development and seeks regulatory approvals[127] - Regulatory approval processes are lengthy, costly, and inherently unpredictable, which could severely impair the group's ability to commercialize its research products[137] - The group may face additional costs or delays in product development if clinical trials do not demonstrate satisfactory safety and efficacy to regulatory authorities[127] - The group’s future growth largely depends on the successful development and commercialization of its research products[127]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 Rainmed Medical Limited 潤 邁 德 醫 療 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2297） 截 至 2022 年 12 月 31 日 止 年 度 之 年 度 業 績 公 告 財務摘要 截至12月31日止年度 2022年 2021年 變動 人民幣百萬元 人民幣百萬元 （百分比除外）（百分比除外） （經審核） （經審核） 收入 83.6 81.2 3.0% 毛利 69.8 69.0 1.2% 毛利率 83.5% 85.0% 本公司股東之應佔虧損 (1,346.0) (633.6) 112.4% 經調整非香港財務報告準則之 本公司股東之應佔虧損附註 (100.9) (51.7) 95.2% ...

Financial Performance - Revenue increased by approximately 17.7% from RMB 440.84 million for the six months ended June 30, 2021, to RMB 518.99 million for the six months ended June 30, 2022, primarily due to increased sales of FlashPressure caFFR pressure sensors[8]. - Gross profit rose from RMB 383 million for the six months ended June 30, 2021, to RMB 448 million for the six months ended June 30, 2022, an increase of about 16.9%[9]. - The net loss for the six months ended June 30, 2022, was RMB 1,210.2 million, compared to a loss of RMB 253.7 million for the six months ended June 30, 2021[23]. - Basic and diluted loss per share was RMB 1.88, compared to RMB 0.40 in the previous year, indicating a deterioration in per-share performance[110]. - The company reported a total comprehensive loss of RMB (1,286,552) thousand[120]. Expenses and Costs - Research and development expenses surged by approximately 254.1%, from RMB 78.93 million for the six months ended June 30, 2021, to RMB 279.51 million for the six months ended June 30, 2022, mainly due to increased employee benefits and R&D material costs[12]. - Sales expenses decreased significantly from RMB 458.6 million for the six months ended June 30, 2021, to RMB 324.5 million for the six months ended June 30, 2022, representing a year-on-year decline of approximately 29.2%[14]. - General and administrative expenses decreased from RMB 601.1 million for the six months ended June 30, 2021, to RMB 471.5 million for the six months ended June 30, 2022, a year-on-year decline of approximately 21.5%[18]. - Employee benefits expenses decreased to RMB 62,727 thousand in H1 2022 from RMB 91,415 thousand in H1 2021, a reduction of approximately 31.4%[172]. - Total expenses for H1 2022 were RMB 114,630 thousand, slightly down from RMB 119,616 thousand in H1 2021, representing a decrease of about 4.1%[172]. Assets and Liabilities - As of June 30, 2022, total assets amounted to RMB 617,952 thousand, a decrease from RMB 640,192 thousand as of December 31, 2021, representing a decline of approximately 3.8%[115]. - Total liabilities reached RMB 2,671,599 thousand as of June 30, 2022, compared to RMB 1,414,676 thousand as of December 31, 2021, marking an increase of approximately 88.7%[117]. - Non-current liabilities increased significantly to RMB 2,630,541 thousand as of June 30, 2022, up from RMB 1,370,609 thousand as of December 31, 2021, reflecting an increase of approximately 92%[117]. - The company has a total equity of RMB (2,053,647) thousand as of June 30, 2022, compared to RMB (774,484) thousand as of December 31, 2021, indicating a significant deterioration in equity position[120]. Cash Flow - Cash and cash equivalents amounted to RMB 518.5 million, a decrease of RMB 40.6 million from RMB 559.1 million as of December 31, 2021[25]. - Operating cash flow for the six months ended June 30, 2022, was RMB (48,456) thousand, compared to RMB (19,110) thousand for the same period in 2021, indicating a worsening cash flow situation[126]. - The company incurred a net cash outflow from investing activities of RMB (12,186) thousand for the six months ended June 30, 2022, compared to RMB (23,672) thousand in the prior year, showing a decrease in cash used for investments[126]. Market and Product Development - The company plans to continue expanding in the Chinese and global markets, focusing on product development through internal growth, mergers, and acquisitions, supported by sufficient bank credit facilities[33]. - The caFFR system has achieved over 95% accuracy and a convenient operation process of less than five minutes, becoming a leading FFR measurement product in China[41]. - The company aims to launch its vascular interventional surgical robot by 2024, integrating all clinical applications for automated PCI processes[41]. - The company is developing the caIMR system, which is the only minimally invasive IMR measurement product that has completed confirmatory clinical trials globally[41]. - The company plans to expand the indications for the caFFR system to include acute STEMI, acute NSTEMI, and HFpEF patients[41]. Corporate Governance - The board of directors consists of two non-executive directors, three independent non-executive directors, and four executive directors, ensuring a balanced distribution of power and authority[61]. - The audit committee, comprising three independent non-executive directors, has reviewed the unaudited interim financial information for the six months ending June 30, 2022[65]. - The company is committed to maintaining high standards of corporate governance to enhance shareholder value and accountability[59]. Shareholder Information - Major shareholders include Opera Rose Limited and Dawning Sky Limited, each holding 214,749,000 shares, representing 18.40% of the company[81]. - The company has multiple shareholders with significant stakes, including Zhou Bin with 82,720,000 shares (7.09%) and Hebei Dongtuo Investment Co., Ltd. with 59,801,000 shares (5.12%)[86]. - The report indicates a diverse ownership structure with various entities holding substantial shares[86]. Regulatory and Compliance - The company was listed on the Hong Kong Stock Exchange on July 8, 2022[129]. - The financial data for the six months ending June 30, 2022, was prepared in accordance with Hong Kong Accounting Standards, specifically HKAS 34[129]. - The company has not recognized any tax provision in mainland China for H1 2022 due to no estimated taxable profits[182].